Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

ARRY 3.83 +0.12 (3.23%)
price chart
3 Reasons to Watch Array Biopharma Inc.
Array's strength in development is their broad target screening methodology. Array has developed a proprietary kinase-inhibitor screening platform to generate new drug leads.
Why Oncotheryeon, Inc., OncoMed Pharmaceuticals, Inc., and Array BioPharma ...
What: Shares of Oncothyreon (NASDAQ: ONTY ) , a developmental biotech, climbed more than 13% today, while fellow biotech stocks OncoMed (NASDAQ: OMED ) and Array BioPharma (NASDAQ: ARRY ) roared higher by as much as 10% and 16.4%, ...
Puma Biotechnology Inc (NYSE:PBYI) Nearly Quadruples, Lifting Cancer ...  Markets Emerging
Related articles »  
Closing Bell Stock Highlights: Paychex, Inc. (PAYX), Array BioPharma, Inc ...
Paychex, Inc. (PAYX) of the Services sector changed by -0.06% today, a change from open of- 0.06% per share with a volume of 1,293,184.
Related articles »  
Morning Briefing on Biotech Stocks - Arrowhead Research, Array BioPharma ...
On Tuesday, shares in Array BioPharma Inc. traded between $3.63 and $3.85 before ending the session 2.70% higher at $3.81. The stock reported a trading volume of 1.71 million shares, above its three months average volume of 1.27 million shares.
Related articles »  
Array BioPharma To Present At The Stifel 2014 Healthcare And Jefferies 2014 ...
10, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY, +2.11% today announced that its Chief Executive Officer, Ron Squarer, will speak at the following upcoming conferences.
Watch List: Array Biopharma Inc (NASDAQ:ARRY), Physicians Realty Trust ...  Techsonian (press release)
Jefferies 2014 Global Healthcare Conference  Virtual Press Office (press release)
Related articles »  
Array BioPharma To Report Financial Results For The First Quarter Of Fiscal ...
BOULDER, Colo., Oct. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY, -2.20% will report financial results for the first quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, November 4, 2014.
Array Biopharma Raised to Outperform at Zacks (ARRY)  Watch List News (press release)
Related articles »  
Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer
11, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY, -3.81% a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced the appointment of ...
Related articles »  
Array BioPharma Inc.: Array BioPharma Reports Financial Results For The First ...
BOULDER, Colo., Nov. 4, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the first quarter of its fiscal year ending June 30, 2015.
Hot Stocks - RealPage , E*TRADE , Array BioPharma , Altera Corp , Catamaran ...  Markets Insider
Related articles »  
Array BioPharma Falls Despite Narrower-than-Expected Q4 Loss
Share price of Array BioPharma Inc. (ARRY - Snapshot Report) fell 5.1% after the company announced its fiscal fourth quarter results on Aug 12.
Array BioPharma Announces Drug Discovery Collaboration Agreement With ...
About Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
Array BioPharma Collaborates with Biogen  Zacks.com
Array BioPharma strikes research pact with Biogen Idec  Denver Business Journal (blog)
Related articles »